XTL Biopharmaceuticals Ltd. : Negotiations for Appointment of a Chief Executive Officer
December 13 2005 - 3:10AM
PR Newswire (US)
REHOVOT, Israel, December 13 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. ("XTLbio")
(LSE:XTL)(NASDAQ:XTLB)(TASE:XTL), a drug discovery and development
company, today announced an update of XTLbio's search for a Chief
Executive Officer. Since March this year, XTLbio has been actively
searching for a US based CEO to lead XTLbio. Following a newspaper
article published in an Israeli evening newspaper on Sunday, XTLbio
confirmed that it is in negotiations with a US based candidate for
the position of CEO of XTLbio. XTLbio indicated that such
negotiations are still ongoing and have not been finalized and
therefore XTLbio did not provide any additional details. About XTL
Biopharmaceuticals Ltd. Established in 1993, XTL Biopharmaceuticals
Ltd. (LSE:XTL)(NASDAQ:XTLB) ( TASE: XTL) is a biopharmaceutical
company engaged in the acquisition, development and
commercialization of pharmaceutical products for the treatment of
infectious diseases, particularly the prevention and treatment of
hepatitis B and C. Cautionary Statement Some of the statements
included in this press release may be forward-looking statements
that involve a number of risks and uncertainties. For those
statements, we claim the protection of the safe harbor for
forward-looking statements contained in the U.S. Private Securities
Litigation Reform Act of 1995. Among the factors that could cause
our actual results to differ materially, and therefore affect
interest by investors in our ADR's, are the following: our ability
to successfully complete cost-effective clinical trials for the
drug candidates in our pipelines and other risk factors identified
from time to time in our reports filed with the regulatory
authorities in Israel, the United Kingdom and the United States.
Any forward-looking statements set forth in this press release
speak only as of the date of this press release. We do not intend
to update any of these forward-looking statements to reflect events
or circumstances that occur after the date hereof. This press
release and prior releases are available at http://www.xtlbio.com/.
The information in our website is not incorporated by reference
into this press release and is included as an inactive textual
reference only. XTLbio Jonathan Burgin, Chief Financial Officer,
Tel: +972-8-930-4440 DATASOURCE: XTL Biopharmaceuticals Ltd.
CONTACT: XTLbio: Jonathan Burgin, Chief Financial Officer, Tel:
+972-8-930-4440
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024